長聖生技聚焦於細胞治療新藥市場與未被滿足的醫療需求，建構具差異化的外泌體新藥開發平台。
透過外泌體在體內精準遞送的技術優勢，長聖發展in vivo CAR-T 等創新免疫治療策略，並進一步拓展至神經退化性疾病等中樞神經系統相關適應症，致力於開創具臨床價值與可規模化潛力的全新治療模式。
Ever Supreme BioTechnology focuses on the cell therapy drug market and areas of unmet medical need, advancing a differentiated exosome-based drug development platform.By leveraging the unique capabilities of exosomes for in vivo delivery, we are developing innovative in vivo CAR-T approaches and expanding our platform toward neurodegenerative and central nervous system indications, aiming to establish clinically meaningful and scalable therapeutic solutions.
醫藥事業：外泌體技術平台
外泌體技術平台
-
CAR.BiTE@CD3e-Nb EV (EXO001)CAR.BiTE@CD3e-Nb EV (EXO001)
長聖EXO001(In Vivo CAR-T)是由基因工程HEK 293T穩定細胞產生的 CD3e Nb-EVs 產品，Nb-CAR.BiTE轉基因可以用來治療 HLA-G 及/...